Bausch Health Companies Inc. (TSE:BHC - Get Free Report) Director John Paulson purchased 754,134 shares of the stock in a transaction dated Tuesday, June 10th. The shares were bought at an average price of C$6.87 per share, with a total value of C$5,179,392.31.
John Paulson also recently made the following trade(s):
- On Friday, June 13th, John Paulson purchased 1,782,030 shares of Bausch Health Companies stock. The shares were bought at an average price of C$8.14 per share, with a total value of C$14,501,803.73.
- On Thursday, June 12th, John Paulson purchased 502,688 shares of Bausch Health Companies stock. The shares were bought at an average price of C$7.44 per share, with a total value of C$3,739,596.57.
- On Wednesday, June 11th, John Paulson purchased 514,549 shares of Bausch Health Companies stock. The shares were bought at an average price of C$7.13 per share, with a total value of C$3,666,881.99.
Bausch Health Companies Trading Down 2.6%
TSE BHC traded down C$0.21 on Tuesday, reaching C$7.80. The company had a trading volume of 373,153 shares, compared to its average volume of 357,009. The firm has a market cap of C$2.03 billion, a price-to-earnings ratio of -11.41, a P/E/G ratio of 0.21 and a beta of 0.77. Bausch Health Companies Inc. has a fifty-two week low of C$5.45 and a fifty-two week high of C$13.74. The business has a 50 day moving average of C$6.74 and a two-hundred day moving average of C$9.08. The company has a debt-to-equity ratio of -1,831.94, a current ratio of 1.19 and a quick ratio of 0.58.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
